Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.
about
Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsStatin drug interactions and related adverse reactions.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs.Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsMechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Induction effects of ritonavir: implications for drug interactions.Renal Drug Transporters and Drug Interactions.Review and analysis of FDA approved drugs using lipid-based formulations.Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes.Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein.Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.Statin drug interactions and related adverse reactions: an update.
P2860
Q33148910-94860015-357F-4AC8-9C77-5B69E369AF9DQ33186873-B902CA8B-3C01-4912-8288-A66E6E8A39A6Q33776536-31D3AFEE-B492-4B38-8F21-01769652F9B7Q33864976-6ACBF10E-2F8D-43D3-A8ED-DA686D676B48Q34292468-C0979F90-3CA9-4BF4-8F7A-9C0D6BD08E4FQ34437996-E374D054-8D5D-470F-9A47-2FE3CD7C5623Q35073349-79CE2AA4-115F-4391-8085-EAABA0664B7AQ35108410-6382867B-75AE-49FD-AB0B-9C641DDC3A23Q35827510-0BF5648B-D5CA-4267-9E29-5DD0AAA8C809Q35827755-1CB79D63-5258-4383-A883-8BEA440AED97Q36072448-5B8A1CC9-7629-4CDC-9113-EFFC655A6E99Q36144257-418C4B6B-7CEC-4C31-BB30-5D0DB83D089FQ36641870-CFC55A0B-B104-479F-8B40-B344F70E90EFQ36641884-10B95F4D-E377-4B93-8704-ECC400827803Q37113947-314D407D-BF49-4680-AE9B-E3217418DD99Q37190767-2C38970D-978C-4FE2-8461-AB6E0B8A3B07Q37199533-D9DE9F1C-31C7-4736-8323-96F37C0ABE96Q39140289-35FF4166-A883-4A45-973B-7837F4C17CEBQ39411779-46287E00-F6E7-49CA-B357-3A11DF975713Q40077147-A6F7A6AC-6CE4-4008-9A31-D0D0AE4FCA96Q41791556-0B23FAB7-28C5-4402-B2FF-BB1B2977C5AEQ43930852-861BE678-D617-424F-AFA2-D0B0AD3F8A2CQ44202487-E600CDF6-E358-471F-888A-00A202D4472BQ44763949-C045A4B2-37A2-4C24-B5FC-ABB40F6000A9Q44777237-B03ECF6E-4327-4600-B55A-C0DFADE410DBQ46543591-11A15063-6F3A-4C16-97AD-954CA605F1E7Q48006398-AEA55C76-289D-4CE2-B9F8-E799FE15F863Q48145497-32B6CAA6-DCF5-4EEE-892A-E6C8A838F985
P2860
Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Ritonavir induces P-glycoprote ...... a human intestinal cell line.
@en
type
label
Ritonavir induces P-glycoprote ...... a human intestinal cell line.
@en
prefLabel
Ritonavir induces P-glycoprote ...... a human intestinal cell line.
@en
P2093
P356
P1476
Ritonavir induces P-glycoprote ...... a human intestinal cell line.
@en
P2093
D J Greenblatt
J E Marchand
L L Von Moltke
P304
P356
10.1002/JPS.1133
P407
P577
2001-11-01T00:00:00Z